You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development and characterization of HIV-1 Tat degraders

    SBC: Thimble Therapeutics Inc            Topic: NIAID

    AbstractDespite effective antiretroviral therapy (ART), latent proviruses can reinitiate viral production upon cell stimulation or treatment interruption. The viral Tat protein enhances transcript elongation from the HIV-1 promoter, controlling the switch between latency and active viral production. The block-and-lock functional cure aims at the transcriptional silencing of the viral reservoir, re ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Leveraging platelet signal transduction for personalized antiplatelet therapy

    SBC: PlateletDiagnostics, LLC            Topic: NHLBI

    Project Summary/Abstract Platelet-mediated thrombosis causes both coronary arterial disease (CAD) and stroke, the first and fifth most common causes of mortality in the US. Antiplatelet agents, typically aspirin and/or clopidogrel, significantly improve survival in patients with CAD or stroke and have remained a mainstay of treatment for more than two decades. Yet despite the consensus that platel ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Protease Stable N-Terminally Modified Therapeutic Peptides

    SBC: VELUM INC            Topic: NIDDK

    PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity, and engender fewer side effects than traditional small molecules. This has fueled interest in peptides filling the gap between ‘biologics’ and small molecules, as peptide-based compounds have key desired properties that are distinct both of the other classes. A major challenge remains to extend the short half-life of na ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Self-Supervised Training in Geospatial Applications with a Robust Hierarchical Vision Transformer (STAR)

    SBC: UNIVERSITY TECHNICAL SERVICES, INC.            Topic: OSD22A001

    Satellite Imagery in Geospatial Intelligence (GEOINT), in conjunction with imagery intelligence (IMINT), geospatial information, and other means of gaining intelligence, has greatly improved the potential of the warfighter and decision makers enabling them to gain a more comprehensive perspective, an in-depth understanding, and a cross-functional awareness of the operational environment. The Artif ...

    STTR Phase I 2022 Department of DefenseNational Geospatial-Intelligence Agency
  5. The First Non-Surgical Anti-Stomal Prolapse Medical Device to Treat and Prevent Stomal Prolapse

    SBC: PEDIATRIC MEDICAL DEVICE COMPANY, LLC            Topic: 300

    ABSTRACT Intestinal stomas such as ileostomies and colostomies are openings of the intestinal tract surgically exteriorized onto the abdominal surface to divert enteric content away from distal cancer, obstruction, inflammation, and infection 5. In the US alone, about 1.5 million people have stomas14. Prolapse, or protrusion, of the bowel through the stoma is a common complication that can cause p ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain

    SBC: Brixton Biosciences, Inc.            Topic: NIAMS

    Project SummaryTotal knee arthroplasty (TKA) is one of the most commonly performed orthopedic surgeries to relieve joint pain in patients with end-stage osteoarthritis or rheumatic arthritis. In the United States, over 700,000 TKA procedures are performed each year. Most patients experience significant pain after TKA. To manage this pain, patients are commonly prescribed opioids, contributing to a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer

    SBC: Up Therapeutics LLC            Topic: 102

    Quadruple negative breast cancer (QNBC), lacking the expression of ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2) and AR (androgen receptor), is the breast cancer subtype with the worst prognosis, and QNBC disproportionately afflicts African Americans. It has no standard-of-care treatment targets and thus efficacious and safe treatments must be ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotics LR-IL-22 and LR-IFN-β

    SBC: CHROMOLOGIC LLC            Topic: R

    Abstract We have developed genetically modified second-generation probiotics for the localized delivery of known mitigators to the GI tract in order to reduce damage and regenerate tissue after exposure to ionizing radiation. Mitigating the effects of ionizing radiation exposure is critical for improving survival in the event of a radiological or nuclear (RAD-NUC) incident, where exposure could le ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting Covid-19 with a Therapeutic Interfering Particle

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYThe Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Development and testing of a behavioral activation mobile therapy for elevated depressivesymptoms

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 104

    PROJECT SUMMARY/ABSTRACT Depression is the leading cause of disability worldwide, with more than 300 million people affected. Most adults with depressive symptoms make at least one annual visit to a primary care physician (PCP). As such, primary care offers a ripe opportunity to identify and treat adults with depressive symptomatology. Yet, depression has historically been undertreated in primary ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government